Today: 22 May 2026
Citigroup stock rises 3% as earnings hangover fades and price targets climb
15 January 2026
1 min read

Citigroup stock rises 3% as earnings hangover fades and price targets climb

New York, January 15, 2026, 10:14 EST — Regular session

Citigroup shares climbed roughly 3.3% to $116.11 in early Thursday trading, rallying past other major U.S. banks following a mixed initial response to its quarterly results.

Investors remain torn on Citi’s value if its overhaul delivers more consistent profits — and whether political and regulatory hurdles will curb potential gains. The stock has shifted quickly from a “fix-it” narrative to a “prove it” challenge.

The deal market’s comeback is a key draw. “We are seeing an accelerating pipeline in M&A and IPOs,” Morgan Stanley CFO Sharon Yeshaya told Reuters. Citi, for its part, is pushing hard into the upswing. Reuters

Citigroup posted fourth-quarter net income of $2.5 billion, or $1.19 per share, on $19.9 billion in revenue, according to an SEC filing. The results factored in a $1.2 billion loss from the planned sale of AO Citibank in Russia. Stripping out that charge, net income rose to $3.6 billion, with earnings per share hitting $1.81. The bank closed 2025 with a common equity tier 1 capital ratio of 13.2%, a key gauge of financial health. CEO Jane Fraser said, “We enter 2026 with visible momentum across the firm,” and reiterated the bank’s 10%-11% return-on-tangible-common-equity target for this year.

Fee businesses drove the beat. Investment banking fees jumped 35% to $1.29 billion, while Citi’s banking unit revenue surged 78% to $2.2 billion, Reuters reported, boosted by stronger dealmaking and corporate services demand. Still, a Russia-related loss pulled Citi’s return on tangible common equity—a key profitability metric—down to 5.1% for the quarter, well short of its target. CEO Jane Fraser said the bank remains focused on exiting Banamex and noted progress on ongoing regulatory matters. “The turnaround story for Citi continues,” said David Wagner, head of equity and portfolio manager at Aptus Capital Advisors.

Certain brokers wasted no time jumping on the opportunity. Oppenheimer’s Chris Kotowski bumped Citi’s price target to $144 from $141, holding firm on his Outperform rating. Piper Sandler also raised its target, from $130 to $135, keeping its Overweight stance intact.

But a policy clash could hit the sector at a delicate moment. Bank leaders have pushed back against U.S. President Donald Trump’s proposal to cap credit-card interest rates at 10%. Fraser said flatly, “A rate cap is not something that we can support,” cautioning it might restrict credit access. Citi CFO Mark Mason added it’s too early to gauge the fallout without more details. Reuters

Citi’s earnings came amid a choppy week for lenders as investors digested mixed results from major banks and debated the rate-cap proposal, even as consumer and corporate borrowing appeared relatively steady.

Citi investors are gearing up for the first-quarter earnings call on April 14, with the bank’s May 7 investor day coming shortly after. Both events will be crucial for Citi to revisit and clarify its 2026 targets.

Stock Market Today

  • Q1 Earnings Review: Azenta Falls; West Pharmaceutical Leads Drug Development Services Stocks
    May 21, 2026, 9:31 PM EDT. Drug development inputs and services stocks, essential for pharmaceutical research and manufacturing, reported mixed Q1 results. Azenta (NASDAQ:AZTA), specializing in biological sample management, posted disappointing results with $144.8 million revenue, missing estimates and the weakest among peers, causing its share price to drop 23.4% to $17.65. Conversely, West Pharmaceutical Services (NYSE:WST), maker of specialized packaging and delivery devices, delivered a strong quarter with $844.9 million revenue, beating estimates by 8.4%. Overall, the sector's revenues beat consensus by 1.6%, despite an average 2.5% share price decline post-earnings. Tailwinds include growth in biologics and gene therapies, while headwinds feature pricing pressure and regulatory risks.

Latest articles

OpenAI Shares Hype Returns, Still No Ticker in Sight

OpenAI Shares Hype Returns, Still No Ticker in Sight

22 May 2026
OpenAI is preparing to confidentially file for a U.S. IPO, aiming to go public as early as September, sources told Reuters. The move follows a court win against Elon Musk, removing a key legal obstacle. Private-market share prices for OpenAI ranged from $658.94 to $732.38 this month, but no official public price exists. Ordinary investors still cannot buy OpenAI stock on public exchanges.
Estée Lauder Shares Gain as Rumored Deal Fails to Materialize

Estée Lauder Shares Gain as Rumored Deal Fails to Materialize

22 May 2026
Estée Lauder and Spain’s Puig ended merger talks that would have created a $40 billion beauty group. Estée Lauder shares rose about 10% in after-hours trading, closing the regular session at $78.91. The company said it will focus on its turnaround plan and continue reviewing possible acquisitions or divestitures.
WhiteFiber Stock Rips 22% on $160 Million AI Deal. The Test Comes in July

WhiteFiber Stock Rips 22% on $160 Million AI Deal. The Test Comes in July

22 May 2026
WhiteFiber shares jumped 22.2% to $29.55 after announcing a five-year AI compute contract worth over $160 million for a Paris-region deployment using NVIDIA GPU systems. Google Finance showed the stock rising further after hours. The project is backed by planned financing and 12 months of customer prepayments, but funding and execution remain pending. Service is expected to start in July, subject to equipment delivery and acceptance.
POET Technologies stock climbs before the bell as call-option volume spikes
Previous Story

POET Technologies stock climbs before the bell as call-option volume spikes

Opendoor Technologies stock slips today as mortgage applications surge and Treasuries stay stubborn
Next Story

Opendoor Technologies stock slips today as mortgage applications surge and Treasuries stay stubborn

Go toTop